BioLineRx News Releases https://ir.biolinerx.com/ BioLineRx News Releases en BioLineRx to Present at the JMP Securities 2019 Life Sciences Conference https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-present-jmp-securities-2019-life-sciences-conference TEL AVIV, Israel , June 13, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the JMP Securities 2019 Life Sciences Thu, 13 Jun 2019 07:00:00 -0400 BioLineRx News Releases 11571 BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-reports-first-quarter-2019-financial-results-and On track for Phase 2 data read-outs in pancreatic cancer and consolidation AML by year-end 2019 Management to hold conference call today, May 14, at 10:00 am EDT TEL AVIV, Israel, May 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company Tue, 14 May 2019 08:00:00 -0400 BioLineRx News Releases 11461 BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-reports-first-quarter-2019-financial-results-and-0 Tue, 14 May 2019 08:00:00 -0400 BioLineRx News Releases 11486 BioLineRx to Report First Quarter 2019 Results on May 14, 2019 https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-report-first-quarter-2019-results-may-14-2019 Management to hold a conference call at 10:00 a.m. EDT Tel Aviv, Israel, May 7, 2019 --- BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its unaudited financial results for the quarter ended March 31, 2019 on Tue, 07 May 2019 08:00:00 -0400 BioLineRx News Releases 11451 BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-fda-approval-ind-application-agi-134-novel-0 Tue, 07 May 2019 08:00:00 -0400 BioLineRx News Releases 11471 BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-fda-approval-ind-application-agi-134-novel - Phase 1/2a study ongoing in the UK and Israel, with sites in the US expected to join by H1 2020 - - Initial safety results expected in H2 2019; initial efficacy results expected by year-end 2020 - TEL AVIV, Israel, May 7, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a Tue, 07 May 2019 08:00:00 -0400 BioLineRx News Releases 11456 BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-reports-year-end-2018-financial-results-and-provides BL-8040 and AGI-134 oncology programs progressing, with multiple data read-outs expected in the next 12 months Management to hold conference call today, March 28, at 10:00 am EDT TEL AVIV, Israel, March 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage Thu, 28 Mar 2019 08:00:00 -0400 BioLineRx News Releases 11436 BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-reports-year-end-2018-financial-results-and-provides-0 Thu, 28 Mar 2019 08:00:00 -0400 BioLineRx News Releases 11491 BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-successful-engraftment-data-phase-3-genesis Results presented as oral presentation at 45th Annual Meeting of European Society for Blood and Marrow Transplantation TEL AVIV, Israel, March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that Wed, 27 Mar 2019 08:00:00 -0400 BioLineRx News Releases 11431 BioLineRx Announces Successful Engraftment Data from Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-successful-engraftment-data-phase-3-0 Wed, 27 Mar 2019 08:00:00 -0400 BioLineRx News Releases 11476